Search results for "Injectable"

showing 10 items of 23 documents

Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Ne…

2022

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with th…

Long-acting injectable antipsychoticCross-Sectional StudiesOff-labelPersonality disorderBipolar disorderDelayed-Action PreparationsSchizophreniaHumansBipolar disorder; Long-acting injectable antipsychotics; Off-label; Personality disorder; Schizophrenia; Cross-Sectional Studies; Delayed-Action Preparations; Humans; Off-Label Use; Antipsychotic Agents; SchizophreniaOff-Label UseSettore MED/25 - PsichiatriaLong-acting injectable antipsychoticsAntipsychotic Agents
researchProduct

Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disor…

2022

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with…

Long-acting injectable antipsychoticPaliperidone palmitate 1-monthAripiprazoleAripiprazole monohydrateLong-acting injectable antipsychoticsPsychiatry and Mental healthPaliperidone PalmitateSchizophreniaHumansProspective StudiesSettore MED/25 - PsichiatriaBiological PsychiatryAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate 1-monthAntipsychotic Agents
researchProduct

Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic…

2021

Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions …

MalePediatricsrespectively)0302 clinical medicineDelayed-Action PreparationBrief Psychiatric Rating ScalePharmacology (medical)he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in ItalyOriginal Research ArticleProspective StudiesProspective cohort studytreatmentMental DisordersHazard ratiowhereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%Psychiatric Status Rating ScaleMiddle Agedside efectsPsychiatry and Mental healthItalyMental DisorderFemalehe STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy occurring in almost 40% of the entire sample; side efects participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4% respectively) whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5% respectively). In multivariate analysis being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk.HumanAntipsychotic Agentsmedicine.drugPsychopathologyAdultmedicine.medical_specialtyDiscontinuationFollow-Up StudieMedication Adherence03 medical and health sciencesmedicineHumansPaliperidoneAdverse effectSettore MED/25 - Psichiatriadiscontinuation ratesPsychiatric Status Rating Scalesrespectively). In multivariate analysisbusiness.industryLong-Acting Antipsychoticlong-acting injectable antipsychoticsSurvival AnalysisConfidence intervalparticipant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%030227 psychiatryDiscontinuationProspective StudieAntipsychotic Agentoccurring in almost 40% of the entire sampleDelayed-Action PreparationsNeurology (clinical)business030217 neurology & neurosurgerybeing prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation riskFollow-Up Studies
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

European Databases on Stability and Compatibility of Injectable Medicinal Products in Europe

2020

AbstractIn hospitals, the majority of medication therapy is administered intravenously. Especially, in intensive care units, simultaneous of various injectable drugs is a common practice Drug incompatibilities have been reported to be associated with up to 60 % of all serious and life-threatening adverse drug events. Several databases are used by hospital pharmacists to answer the questions of (in)compatibility of co-administered injectable drugs. The objective of this article is to present the European databases on compatibility and stability of injectable drugs. According to a questionnaire which was sent to the National Hospital Pharmacy Associations of the 28 countries of European Commu…

Pharmacologybusiness.industryelectronic databasePharmacyRM1-950compatibility030226 pharmacology & pharmacyBiotechnologychemical stability03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisCompatibility (mechanics)MedicinePharmacology (medical)Electronic databaseTherapeutics. PharmacologyHD9665-9675businessinjectable drugsPharmaceutical industryPharmaceutical Technology in Hospital Pharmacy
researchProduct

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

2021

Background: Long-acting injectable (LAI) antipsychotics are efficacious in managing psychotic symptoms in people affected by severe mental disorders, such as schizophrenia and bipolar disorder. The present study aimed to investigate whether attitude toward treatment and treatment adherence represent predictors of symptoms changes over time.Methods: The STAR Network “Depot Study” was a naturalistic, multicenter, observational, prospective study that enrolled people initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centers were assessed at three time points: baseline, 6-month, and 12-month follow-up. Psychopathological symptoms, att…

Psychiatrypsychotic symptomtherapeutic allianceRC435-571drugantipsychoticPsychiatry and Mental healthantipsychoticsadherence; antipsychotics; attitude; drug; long-acting injectable; psychotic symptoms; therapeutic alliancepsychotic symptomsattitudeadherencelong-acting injectableOriginal ResearchFrontiers in Psychiatry
researchProduct

Injectable hydrogel formulations to host adipose stem cell spheroids for stemness maintenance and bone and cartilage regeneration

2021

Adipose-derived mesenchymal stem cells (ASCs) represent a great promise for tissue regeneration as fat is a very abundant source of stem cells (1) and owing to their ability to self-renew and differentiate into specific tissue types (2). In general, they are usually cultured as two-dimensional (2D) adherent monolayers, not representative of the in vivo condition, often entailing lower cell viability and, more in general, a lower “cell quality” in terms of regenerative potential (3, 4). When ASCs are cultured in low adhesion flasks and with a suitable culture medium, they aggregate in the form of three-dimensional spheroids (SASCs). The incorporation of these spheroids into injectable, in-si…

Settore CHIM/07 - Fondamenti Chimici Delle TecnologieSpheroids of adipose stem cells artificial niche in-situ forming gel partially degalactosylated xyloglucan injectable hydrogels
researchProduct

Adipose stem cell spheroids-laden hydrogels for minimally invasive bone and cartilage regeneration interventions

2021

Spheroids of adipose stem cells Xyloglucan Injectable hydrogels Osteogenic differentiation Chondroblastic differentiationSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

Data from: Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

2019

Background. For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to explore possible prescribing differences between first- and second-generations LAIs under ordinary clinical practice in Italy. Methods. The STAR Network "Depot" Study is an observational, longitudin…

bipolar disorderpharmacoepidemiologyvirusesLife Sciencesvirus diseaseslong-acting injectable antipsychoticsadherence to antipsychoticsDecember 2015-May 2017medicine and health careschizophreniaantipsychoticsimmune system diseasesMedicineoff-label prescriptionsdepot antipsychotics
researchProduct